Status:
COMPLETED
Systemic Inflammation in Liver Cirrhosis
Lead Sponsor:
Third Affiliated Hospital, Sun Yat-Sen University
Collaborating Sponsors:
National Natural Science Foundation of China
Conditions:
Liver Cirrhosis
Eligibility:
All Genders
18-75 years
Brief Summary
Investigate systemic inflammation in liver cirrhosis patients
Eligibility Criteria
Inclusion
- Decompensated liver cirrhosis, with endoscopy-verified high-risk esophagogastric varices;
- Adult patients aged 18-75 years;
- Willing to anticipate and informed consent form obtained
Exclusion
- History of prior radio-interventional therapy (TIPS or BRTO), liver transplantation, splenectomy, or hepatectomy;
- Non-sinusoidal cirrhosis (e.g. vascular cirrhosis);
- Coexistence with advanced hepatocellular carcinoma or other malignancies;
- Coexistence with severe systemic diseases and less than 3 months of expected survival time;
- Acute infection within 4 weeks before recruitment;
- Antibiotic use within 4 weeks before recruitment;
- Initial antiviral therapy for HBV or HCV within 4 weeks before recruitment;
- Pregnant or lactating women;
- Patients resistant to long-term follow-up
Key Trial Info
Start Date :
April 1 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 30 2023
Estimated Enrollment :
400 Patients enrolled
Trial Details
Trial ID
NCT04850534
Start Date
April 1 2019
End Date
October 30 2023
Last Update
December 6 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Cardiology, the Third Affiliated Hospital, Sun Yat-sen University
Guangzhou, Guangdong, China, 510630